# Eryaspase

Source: https://onco.cc/drugs/eryaspase/  
OnCo record `eryaspase` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eryaspase packed a leukaemia enzyme into red blood cells to starve pancreatic cancer of an amino acid; the phase 3 TRYbeCA-1 trial missed its survival goal.

## Summary

Erytech Pharma, now part of Phaxiam, built eryaspase for tumours that cannot make their own asparagine. A randomised phase 2 in second-line pancreatic cancer had shown longer survival, which led to the phase 3 TRYbeCA-1 trial of eryaspase with chemotherapy against chemotherapy alone in the second line.

TRYbeCA-1 reported in 2021: overall survival was not significantly improved, and the pancreatic programme ended.

## Fields

- Kind: Treatment
- Status: negative
- Last checked: 2026-09-17
- Also known as: GRASPA; L-asparaginase encapsulated in red blood cells
- Code: GRASPA
- Modality: L-asparaginase encapsulated in donor red blood cells
- Mechanism: Depletes circulating asparagine, an amino acid that pancreatic tumours with low asparagine synthetase cannot make, while the red-cell shell protects the enzyme and reduces toxicity.

## Sources

- ClinicalTrials.gov NCT03665441: https://clinicaltrials.gov/study/NCT03665441

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- companies: [Phaxiam Therapeutics (formerly ERYtech Pharma)](https://onco.cc/companies/phaxiam/)
- trials: [TRYbeCA-1](https://onco.cc/trials/trybeca-1/)

---
JSON: https://onco.cc/api/v1/entities/eryaspase.json